Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

Brian Arends, left, checks the electrical resistivity and conductivity of the wearable heart monitor as Zheng Yan, center, and Yadong Xu, right, observe in Yan's lab. The lab is located in the Roy Blunt NextGen Precision Health building. Pate McCuien/University of Missouri

News | Wearables

University of Missouri Researchers Design New Heart Health Wearable

December 7, 2022 — While heart disease is a leading cause of death in the United States, most people can be treated ...

December 07, 2022

News | Clinical Decision Support

Computerized Decision Support System Helps to Reduce Cardiovascular Risk Factors in Patients with Diabetes

December 7, 2022 — Compared with team-based care alone, the addition of a computerized clinical decision support system ...

December 07, 2022

Allogeneic CardiALLO therapy for heart failure to complement autologous cell therapy currently enrolling in Phase III CardiAMP Heart Failure clinical trial

News | Heart Failure

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

December 7, 2022 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

December 07, 2022

News | Cardiovascular Business

Ultromics Receives FDA Clearance for AI-based Platform for Echocardiography

December 7, 2022 — Ultromics has announced that its EchoGo Heart Failure, an artificial intelligence (AI) platform for ...

December 07, 2022

Designed to assist physicians detect findings on chest X-rays suggestive of Aortic Atherosclerosis and Aortic Ectasia.

News | Endovascular Aortic Repair

Imagen Technologies Announces FDA Clearance of Aorta-CAD

December 5, 2022 — Imagen Technologies, Inc. announced the U.S. Food and Drug Administration's 510(k) clearance of the ...

December 05, 2022

Feature | Cardiovascular Business

Top 10 Most-read Content in November

Here is a recap of what DAIC viewers found most interesting during the month of November:

1. Study Finds That Risk of ...

December 05, 2022

Ms. Nieves, donor family, and doctors. Photo courtesy of Montefiore Health System.

News | Heart Failure

World's First HIV-Positive to HIV-Positive Heart Transplant Recipient Meets Donor Family, Shares Gratitude for Life & Advocates for Organ Donation

December 2, 2022 — Westchester resident, 62-year-old Miriam Nieves, is especially grateful this Thanksgiving season ...

December 02, 2022

Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic Valve System.

News | Structural Heart

Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2 Aortic Valve System

December 2, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

December 02, 2022

Last year, U.S. Congressman Andy Barr (KY-06) introduced this legislation in the House to honor the legacy of his wife, Carol Leavell Barr, who passed away tragically from sudden cardiac death brought on by mitral valve prolapse, an underlying heart condition that causes death in .2% of cases.

News | Heart Failure

CAROL Act Will Prioritize Research on Heart Valve Disease

December 2, 2022 — The U.S. Senate today passed the bipartisan Cardiovascular Advances in Research and Opportunities ...

December 02, 2022

Transverse heart sections from wild type mice (WT) and transgenic mice overexpressing beta-3 adrenergic receptor in cardiomyocytes (c-hB3tg) after 3 months of aortic stenosis (transaortic constriction, TAC) or control (sham). Hypertrophy after TAC was less severe in the transgenic mice. Courtesy of CNIC

News | Heart Failure

A New Therapeutic Target for the Prevention of Heart Failure Due to Aortic Stenosis

December 1, 2022 — Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified a new ...

December 01, 2022

News | ECMO Systems

Cardiothoracic Surgeon to Lead Smidt Heart Institute's ECMO Program

November 30, 2022 — The Smidt Heart Institute at Cedars-Sinai has selected board-certified cardiothoracic surgeon Tyler ...

November 30, 2022

News | Structural Heart

Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2 Aortic Valve System

November 30, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

November 30, 2022

News | Structural Heart

Medtronic’s Next-Gen Evolut FX TAVR System Shows Significant Improvement in Commissure Alignment in Real World Setting

November 30, 2022 — Medtronic’s newest generation self-expanding, transcatheter aortic valve replacement (TAVR) system ...

November 30, 2022

News | Cardiac Imaging

AI Predicts Heart Disease Risk Using Single X-Ray

November 29, 2022 — Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10 ...

November 29, 2022

Tanya Therapeutics announced today that the US FDA has granted orphan drug designation for its second gene therapy product candidate, TN-401, for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC)

News | Pharmaceuticals

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

November 28, 2022 – Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and ...

November 28, 2022